Novo Nordisk shares slide as investors question growth and pipeline

Danish group targets more blockbuster drugs as semaglutide patents near expiry

Novo Nordisk shares slide as investors question growth and pipeline
Danish group targets more blockbuster drugs as semaglutide patents near expiry